Bolt Biotherapeutics completed its acquisition of Prana Therapies and raised $120 million in private financing, making Prana's pipeline the company's primary focus. Their lead drug, PRA-216, a bispecific antibody targeting IL-4Rα/TSLP, is now in Phase 2 trials for asthma, atopic dermatitis, COPD, and soon eosinophilic esophagitis, with initial data expected in Q2 2027. The acquisition and financing provide Bolt with the capital to advance multiple clinical and preclinical milestones through 2028. This marks a strategic shift to develop next-generation multispecific antibody therapies with convenient dosing schedules.
Bolt Biotherapeutics' recent acquisition and financing news come as Pluang's Health sector shows broad declines, with only 23 of 150 US stocks rising as of Nov 13, 2026 04:11 WIB. For readers following health stocks, here is Pluang's market snapshot: ClearPoint Neuro Inc (CLPT) fell 7.74% to USD 8.46 with 100% sell orders, Nuwellis Inc (NUWE) dropped 7.59% to USD 5.11 also with 100% sell orders, and Moderna, Inc. (MRNA) declined 7.13% to USD 230.95 with a 58% sell order activity and typical hold time of 58 days.
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
Cisco is set to report its fiscal Q1 2027 earnings with a focus on cloud growth and AI demand. Analysts expect revenue around $18.1 billion, operating income of $6.5 billion, and earnings per share of $1.33, reflecting strong year-over-year growth. T...
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
